Skip to main content

Dan Ferry

Analyst

LifeSci Advisors

Head of Investor Relations

Mineralys Therapeutics, Inc. (MLYS)

Head of Investor Relations

Viridian Therapeutics, Inc.\DE (VRDN)

Equibles does not estimate personal net worth.

About Dan Ferry

Dan Ferry is recorded as Analyst at LifeSci Advisors, Head of Investor Relations at Mineralys Therapeutics, Inc. (MLYS) and Head of Investor Relations at Viridian Therapeutics, Inc.\DE (VRDN). Dan Ferry has spoken on 24 earnings calls across 4 companies, most recently for Mineralys Therapeutics, Inc. on November 4, 2026. Those appearances were for CorMedix Inc. (CRMD), Mineralys Therapeutics, Inc. (MLYS), X4 Pharmaceuticals, Inc (XFOR) and Rain Enhancement Technologies Holdco, Inc. (RAIN). Mineralys Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Viridian Therapeutics, Inc.\DE is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Dan Ferry spoke on are classified in the Healthcare and Industrials sectors. Other leadership on record at Mineralys Therapeutics, Inc. includes Jon Congleton (CEO and Board Member), Glenn P. Sblendorio (Chairman), Alexander Gold (Board Member) and 6 others.

Dan Ferry on recent calls

“I would like to welcome everyone joining us today for our third quarter 2026 conference call. This afternoon, after the close of market trading, we issued a press release providing our third quarter 2026 financial results and business updates.”
Head of Investor Relations, Third Quarter 2026 Earnings Call ·
“I would like to welcome everyone joining us today for our second quarter 2026 conference call. This afternoon, after the close of market trading, we should have a press release providing our second quarter 2026 financial results and business updates.”
Head of Investor Relations, Second Quarter 2026 Earnings Call ·
“I would like to welcome everyone joining us today for our fourth quarter and full year 2025 conference call. This afternoon, after the close of market trading, we issued a press release providing our fourth quarter and full year 2025 financial results and business updates.”
Head of Investor Relations, Mineralys Therapeutics, Inc. Q4 FY2025 Earnings Call ·
“Presenting on today's call will be X4's Chief Executive Officer, Dr. Paula Ragan; and Chief Financial Officer, Adam Mostafa. Following prepared remarks by each, we will open the call to your questions, and will be joined by Chief Commercial Officer, Mark Baldry; and Chief Medical Officer, Dr. Christophe Arbet-Engels.”
Host, X4 Pharmaceuticals, Inc Q1 FY2025 Earnings Call ·
“Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix.”
Analyst — LifeSci Advisors, CorMedix Inc. Q1 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Mineralys Therapeutics, Inc.

Leadership on record at Viridian Therapeutics, Inc.\DE

Recent activity

Show 12 earlier activities